| Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (−)-epigallocatechin gallate A Dube, JA Nicolazzo, I Larson European Journal of Pharmaceutical Sciences 41 (2), 219-225, 2010 | 312 | 2010 |
| Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution A Dube, K Ng, JA Nicolazzo, I Larson Food chemistry 122 (3), 662-667, 2010 | 205 | 2010 |
| Nanomedicine: past, present and future–a global perspective EH Chang, JB Harford, MAW Eaton, PM Boisseau, A Dube, R Hayeshi, ... Biochemical and biophysical research communications 468 (3), 511-517, 2015 | 171 | 2015 |
| Chitosan nanoparticles enhance the plasma exposure of (−)-epigallocatechin gallate in mice through an enhancement in intestinal stability A Dube, JA Nicolazzo, I Larson European Journal of Pharmaceutical Sciences 44 (3), 422-426, 2011 | 152 | 2011 |
| Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases A Dube, JL Reynolds, WC Law, CC Maponga, PN Prasad, GD Morse Nanomedicine: Nanotechnology, biology and medicine 10 (4), 831-838, 2014 | 95 | 2014 |
| Establishment of the African Medicines Agency: progress, challenges and regulatory readiness BM Ncube, A Dube, K Ward Journal of pharmaceutical policy and practice 14 (1), 29, 2021 | 73 | 2021 |
| Nanotechnology advances towards development of targeted-treatment for obesity NRS Sibuyi, KL Moabelo, M Meyer, MO Onani, A Dube, AM Madiehe Journal of nanobiotechnology 17, 1-21, 2019 | 66 | 2019 |
| Recent advances in the development of antimicrobial and antifouling biocompatible materials for dental applications P Ramburrun, NA Pringle, A Dube, RZ Adam, S D’Souza, M Aucamp Materials 14 (12), 3167, 2021 | 64 | 2021 |
| Curdlan-conjugated PLGA nanoparticles possess macrophage stimulant activity and drug delivery capabilities M Tukulula, R Hayeshi, P Fonteh, D Meyer, A Ndamase, MT Madziva, ... Pharmaceutical research 32, 2713-2726, 2015 | 60 | 2015 |
| The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy RE Maphasa, M Meyer, A Dube Frontiers in Cellular and Infection Microbiology 10, 618414, 2021 | 46 | 2021 |
| Preparation and evaluation of pralidoxime-loaded PLGA nanoparticles as potential carriers of the drug across the blood brain barrier W Chigumira, P Maposa, LL Gadaga, A Dube, D Tagwireyi, CC Maponga Journal of Nanomaterials 2015, 8-8, 2015 | 41 | 2015 |
| State of the art and future directions in nanomedicine for tuberculosis A Dube, Y Lemmer, R Hayeshi, M Balogun, P Labuschagne, H Swai, ... Expert Opinion on Drug Delivery 10 (12), 1725-1734, 2013 | 39 | 2013 |
| Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin T Samkange, S D'Souza, K Obikeze, A Dube Journal of Pharmacy and Pharmacology 71 (10), 1497-1507, 2019 | 38 | 2019 |
| Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice P Melariri, L Kalombo, P Nkuna, A Dube, R Hayeshi, B Ogutu, L Gibhard, ... International journal of nanomedicine, 1493-1503, 2015 | 38 | 2015 |
| Mycobacterium tuberculosis and interactions with the host immune system: opportunities for nanoparticle based immunotherapeutics and vaccines RB Bekale, SM Du Plessis, NJ Hsu, JR Sharma, SL Sampson, M Jacobs, ... Pharmaceutical research 36, 1-15, 2019 | 33 | 2019 |
| Encapsulation of variabilin in stearic acid solid lipid nanoparticles enhances its anticancer activity in vitro MS Lerata, S D’Souza, NRS Sibuyi, A Dube, M Meyer, T Samaai, ... Molecules 25 (4), 830, 2020 | 32 | 2020 |
| Functionalization of PLGA Nanoparticles with 1, 3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages M Tukulula, L Gouveia, P Paixao, R Hayeshi, B Naicker, A Dube Pharmaceutical research 35, 1-11, 2018 | 25 | 2018 |
| Encapsulation of isoniazid in chitosan-gum arabic and poly (lactic-co-glycolic acid) PVA particles to provide a sustained release formulation P Kadare, P Maposa, A Dube, CC Maponga J. Pharm. Pharmacol 1, 01-06, 2014 | 23 | 2014 |
| Formulation and characterization of a paediatric nanoemulsion dosage form with modified oral drug delivery system for improved dissolution rate of nevirapine TE Manyarara, S Khoza, A Dube, CC Maponga MRS Advances 3 (37), 2203-2219, 2018 | 21 | 2018 |
| The Design and Evaluation of Placebo Material for Crude Herbals: Artemisia afra Herb as a Model A Dube, LN Manthata, JA Syce Phytotherapy Research: An International Journal Devoted to Pharmacological …, 2007 | 21 | 2007 |
